Patrick Baeuerle is a German molecular biologist, Honorary Professor for Immunology at the University of Munich, and Chief Scientific Officer of the biopharmaceutical company Micromet, Incorporated. According to a survey of the Institute for Scientific Information, he was Germany’s most frequently cited biomedical researcher from 1991–2000, and ranked 38th worldwide.
Education
Patrick Baeuerle studied biology at the University of Konstanz, Germany. He did his Doctor of Philosophy work with Wieland B. Huttner at the Max Planck Institute of Neurobiology in Martinsried, Germany, and at the European Molecular Biology Laboratory in Heidelberg, and received his Doctor of Philosophy degree (summa cum laude) from the Ludwig Maximilian University of Munich. His postdoctoral training was with Nobel laureate David Baltimore at the Whitehead Institute in Cambridge, Massachusetts.
Career
He has an h-index of 87 points. Patrick Baeuerle did seminal work on tyrosine sulfation of proteins, transcription factor Newfoundland-kappaB, and on development of bi-specific T-cell engagers for therapy of cancer. In 1989, Patrick Baeuerle started an independent research group at Klinikum Großhadern in Martinsried, Germany.
In 1993, he became Chair of Biochemistry and Molecular Biology at the medical school of University of Freiburg.
Three years later, he joined the start-up company Tularik in South San Francisco as its Director of Drug Discovery. In 1998, he moved back to Germany to head research and development of Micromet AG, a Munich-based biopharmaceutical company.
By acquisition of CancerVax in 2006, Patrick Baeuerle became Chief Scientific Officer of National Association of Securities Dealers Automated Quotation -listed Micromet now headquartered in Bethesda, Maryland, with a research centre in Munich, Germany. As a student, Patrick Baeuerle showed that tyrosine sulfation is a transport-Golgi-specific modification of secretory proteins.
As a postdoctoral fellow, he discovered the inhibitory subunit I-kappa Bachelor of transcription factor Newfoundland-kappa B, and became inventor of the controversial Newfoundland-kappa B patent ‘516.
His own research group studied the function of purified I-kappaB proteins, supported cloning of Newfoundland-kappa B subunits p50 and p65/RelA, identified Newfoundland-kappa as a redox-controlled transcription factor demonstrated the transport-activating potential of p65/RelA, showed that Newfoundland-kappa B is binding to deoxyribonucleic acid as a heterodimer, studied how I-kappa B proteins control nuclear translocation of Newfoundland-kappaB, and unravelled the basic mechanism of Newfoundland-kappa B activation, involving phosphorylation of I-kappa B and its subsequent degradation by the proteasome. His group was also first to show that Newfoundland-kappa B plays a functional role in the nervous system. Patrick Baeuerle authored more than 150 publications on Newfoundland-kappa B and related research.
Since 1998, Patrick Baeuerle investigates the therapeutic potential of T cell-engaging BiTE antibodies for therapy of cancer, and has been responsible at Micromet for the development of blinatumomab and several other antibody therapies.
He authored more than 210 publications (Search in PubMed with author name “baeuerle p”).